A Study of TG103 Injection in Non-diabetic Overweight or Obesity

Summary

This study is a multicenter, randomized, double-blind, placebo-controlled, parallel phase 3 study to evaluate efficacy, safety, pharmacokinetics characteristics and immunogenicity of TG103 injection, a GLP-1 receptor agonist, for weight management in non-diabetic patients with BMI greater than or equal to 28 kg/m2 or greater than 24 kg/m2 in the presence of comorbidities, in addition to lifestyle intervention (calorie restrict diet and increased physical activity).

Timeline

Start

2023-11-22

Primary completion

2025-02-17

Completion

2025-03-03

Drugs

Indications